C-Fms-mediated differentiation and priming of monocyte lineage cells play a central role in autoimmune arthritis

Arthritis Research and Therapy

Volumn 12, Issue 1, 2010, Pages

  Paniagua, Ricardo T ^a,b   Chang, Anna ^a,b   Mariano, Melissa M ^a,b   Stein, Emily A ^a,b   Wang, Qian ^a,b   Lindstrom, Tamsin M ^a,b   Sharpe, Orr ^a,b   Roscow, Claire ^a,b   Ho, Peggy P ^a   Lee, David M ^c   Robinson, William H ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; COLONY STIMULATING FACTOR; COLONY STIMULATING FACTOR RECEPTOR; GW 2580; IMATINIB; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; 5 (3 METHOXY 4 ((4 METHOXYBENZYL)OXY)BENZYL)PYRIMIDINE 2,4 DIAMINE; 5-(3-METHOXY-4-((4-METHOXYBENZYL)OXY)BENZYL)PYRIMIDINE-2,4-DIAMINE; ANISOLE DERIVATIVE; COLONY STIMULATING FACTOR 1; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DIFFERENTIATION; CELL INFILTRATION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FOREFOOT; HISTOLOGY; IN VIVO STUDY; MACROPHAGE; MALE; MOUSE; NONHUMAN; OSTEOARTHRITIS; OSTEOCLAST; OSTEOLYSIS; PROTEIN PHOSPHORYLATION; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID; ANIMAL; ARTHRITIS; BAGG ALBINO MOUSE; CELL LINEAGE; CYTOLOGY; DBA MOUSE; DRUG EFFECT; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; INFLAMMATION; MACROPHAGE ACTIVATION; METABOLISM; MONOCYTE; ONCOGENE; PATHOLOGY;

ANIMALS; ANISOLES; ANTIRHEUMATIC AGENTS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; BONE RESORPTION; CELL DIFFERENTIATION; CELL LINEAGE; GENES, FMS; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MACROPHAGE ACTIVATION; MACROPHAGE COLONY-STIMULATING FACTOR; MACROPHAGES; MICE; MICE, INBRED BALB C; MICE, INBRED DBA; MONOCYTES; OSTEOCLASTS; PIPERAZINES; PYRIMIDINES; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR;

EID: 77953269844     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2940     Document Type: Article

References (47)

1. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003, 423:356-361. 10.1038/nature01661, 12748655.
2. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, Burge DJ. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999, 340:253-259. 10.1056/NEJM199901283400401, 9920948.
3. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004, 350:2572-2581. 10.1056/NEJMoa032534, 15201414.
4. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, Birbara C, Box J, Natarajan K, Nuamah I, Li T, Aranda R, Hagerty DT, Dougados M. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005, 353:1114-1123. 10.1056/NEJMoa050524, 16162882.
5. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001, 344:1031-1037. 10.1056/NEJM200104053441401, 11287972.
6. Demetri GD, von Mehren M, Blanke CD, Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002, 347:472-480. 10.1056/NEJMoa020461, 12181401.
7. Ames PR, Aye WW, Beatty C, O'Reilly D. Imatinib treatment of seropositive arthritis in a young woman with chronic myeloid leukemia. J Rheumatol 2008, 35:1682.
8. Miyachi K, Ihara A, Hankins RW, Murai R, Maehiro S, Miyashita H. Efficacy of imatinib mesylate (STI571) treatment for a patient with rheumatoid arthritis developing chronic myelogenous leukemia. Clin Rheumatol 2003, 22:329-332. 10.1007/s10067-003-0716-3, 14576993.
9. Eklund KK, Joensuu H. Treatment of rheumatoid arthritis with imatinib mesylate: clinical improvement in three refractory cases. Ann Med 2003, 35:362-367. 10.1080/07853890310001339, 12952023.
10. Koyama K, Hatsushika K, Ando T, Sakuma M, Wako M, Kato R, Haro H, Sugiyama H, Hamada Y, Ogawa H, Nakao A. Imatinib mesylate both prevents and treats the arthritis induced by type II collagen antibody in mice. Mod Rheumatol 2007, 17:306-310. 10.1007/s10165-007-0592-9, 17694264.
11. Ando W, Hashimoto J, Nampei A, Tsuboi H, Tateishi K, Ono T, Nakamura N, Ochi T, Yoshikawa H. Imatinib mesylate inhibits osteoclastogenesis and joint destruction in rats with collagen-induced arthritis (CIA). J Bone Miner Metab 2006, 24:274-282. 10.1007/s00774-006-0684-1, 16816921.
12. Paniagua RT, Sharpe O, Ho PP, Chan SM, Chang A, Higgins JP, Tomooka BH, Thomas FM, Song JJ, Goodman SB, Lee DM, Genovese MC, Utz PJ, Steinman L, Robinson WH. Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J Clin Invest 2006, 116:2633-2642. 1564430, 16981009.
13. Buchdunger E, Matter A, Druker BJ. Bcr-Abl inhibition as a modality of CML therapeutics. Biochim Biophys Acta 2001, 1551:M11-18.
14. Dewar AL, Cambareri AC, Zannettino AC, Miller BL, Doherty KV, Hughes TP, Lyons AB. Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood 2005, 105:3127-3132. 10.1182/blood-2004-10-3967, 15637141.
15. Fabian MA, Biggs WH, Treiber DK, Atteridge CE, Azimioara MD, Benedetti MG, Carter TA, Ciceri P, Edeen PT, Floyd M, Ford JM, Galvin M, Gerlach JL, Grotzfeld RM, Herrgard S, Insko DE, Insko MA, Lai AG, Lelias JM, Mehta SA, Milanov ZV, Velasco AM, Wodicka LM, Patel HK, Zarrinkar PP, Lockhart DJ. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005, 23:329-336. 10.1038/nbt1068, 15711537.
16. Serbina NV, Jia T, Hohl TM, Pamer EG. Monocyte-mediated defense against microbial pathogens. Annu Rev Immunol 2008, 26:421-452. 10.1146/annurev.immunol.26.021607.090326, 18303997.
17. Pixley FJ, Stanley ER. CSF-1 regulation of the wandering macrophage: complexity in action. Trends Cell Biol 2004, 14:628-638. 10.1016/j.tcb.2004.09.016, 15519852.
18. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003, 423:337-342. 10.1038/nature01658, 12748652.
19. Yao Z, Li P, Zhang Q, Schwarz EM, Keng P, Arbini A, Boyce BF, Xing L. Tumor necrosis factor-alpha increases circulating osteoclast precursor numbers by promoting their proliferation and differentiation in the bone marrow through up-regulation of c-Fms expression. J Biol Chem 2006, 281:11846-11855. 10.1074/jbc.M512624200, 16461346.
20. Yang PT, Kasai H, Xiao WG, Zhao LJ, He LM, Yamashita A, Deng XW, Ito M. Increased expression of macrophage colony-stimulating factor in ankylosing spondylitis and rheumatoid arthritis. Ann Rheum Dis 2006, 65:1671-1672. 10.1136/ard.2006.054874, 1798478, 17105859.
21. Nakano K, Okada Y, Saito K, Tanikawa R, Sawamukai N, Sasaguri Y, Kohro T, Wada Y, Kodama T, Tanaka Y. Rheumatoid synovial endothelial cells produce macrophage colony-stimulating factor leading to osteoclastogenesis in rheumatoid arthritis. Rheumatology (Oxford) 2007, 46:597-603. 10.1093/rheumatology/kel356, 17062647.
22. Lin H, Lee E, Hestir K, Leo C, Huang M, Bosch E, Halenbeck R, Wu G, Zhou A, Behrens D, Hollenbaugh D, Linnemann T, Qin M, Wong J, Chu K, Doberstein SK, Williams LT. Discovery of a cytokine and its receptor by functional screening of the extracellular proteome. Science 2008, 320:807-811. 10.1126/science.1154370, 18467591.
23. Rosloniec EF, Kang AH, Myers LK, Cremer MA. Collagen-induced arthritis. Current Protocols in Immunology 1994, 1515.11-15.15.24. Hoboken, NJ: John Wiley and Sons, Inc, Coico R, Shevach E.
24. Deng GM, Zheng L, Chan FK, Lenardo M. Amelioration of inflammatory arthritis by targeting the pre-ligand assembly domain of tumor necrosis factor receptors. Nat Med 2005, 11:1066-1072. 10.1038/nm1304, 16170321.
25. Shin K, Gurish MF, Friend DS, Pemberton AD, Thornton EM, Miller HR, Lee DM. Lymphocyte-independent connective tissue mast cells populate murine synovium. Arthritis Rheum 2006, 54:2863-2871. 10.1002/art.22058, 16947397.
26. Shin K, Nigrovic PA, Crish J, Boilard E, McNeil HP, Larabee KS, Adachi R, Gurish MF, Gobezie R, Stevens RL, Lee DM. Mast cells contribute to autoimmune inflammatory arthritis via their tryptase/heparin complexes. J Immunol 2009, 182:647-656. 2610352, 19109198.
27. Stanley ER. Murine bone marrow-derived macrophages. Methods Mol Biol 1997, 75:301-304.
28. Hamerman JA, Tchao NK, Lowell CA, Lanier LL. Enhanced Toll-like receptor responses in the absence of signaling adaptor DAP12. Nat Immunol 2005, 6:579-586. 10.1038/ni1204, 1282462, 15895090.
29. Conway JG, McDonald B, Parham J, Keith B, Rusnak DW, Shaw E, Jansen M, Lin P, Payne A, Crosby RM, Johnson JH, Frick L, Lin MH, Depee S, Tadepalli S, Votta B, James I, Fuller K, Chambers TJ, Kull FC, Chamberlain SD, Hutchins JT. Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580. Proc Natl Acad Sci USA 2005, 102:16078-16083. 10.1073/pnas.0502000102, 1276040, 16249345.
30. Conway JG, Pink H, Bergquist ML, Han B, Depee S, Tadepalli S, Lin P, Crumrine RC, Binz J, Clark RL, Selph JL, Stimpson SA, Hutchins JT, Chamberlain SD, Brodie TA. Effects of the cFMS kinase inhibitor 5-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine (GW2580) in normal and arthritic rats. J Pharmacol Exp Ther 2008, 326:41-50. 10.1124/jpet.107.129429, 18434589.
31. Gredmark S, Britt WB, Xie X, Lindbom L, Soderberg-Naucler C. Human cytomegalovirus induces inhibition of macrophage differentiation by binding to human aminopeptidase N/CD13. J Immunol 2004, 173:4897-4907.
32. Irvine KM, Burns CJ, Wilks AF, Su S, Hume DA, Sweet MJ. A CSF-1 receptor kinase inhibitor targets effector functions and inhibits pro-inflammatory cytokine production from murine macrophage populations. FASEB J 2006, 20:1921-1923. 10.1096/fj.06-5848fje, 16877523.
33. Xu W, Schlagwein N, Roos A, Berg TK, Daha MR, van Kooten C. Human peritoneal macrophages show functional characteristics of M-CSF-driven anti-inflammatory type 2 macrophages. Eur J Immunol 2007, 37:1594-1599. 10.1002/eji.200737042, 17474153.
34. Monach PA, Hueber W, Kessler B, Tomooka BH, Benbarak M, Simmons BP, Wright J, Thornhill TS, Monestier M, Ploegh H, Robinson WH, Mathis D, Benoist C. A broad screen for targets of immune complexes decorating arthritic joints highlights deposition of nucleosomes in rheumatoid arthritis. Proc Natl Acad Sci USA 2009, 106:15867-15872. 10.1073/pnas.0908032106, 2747210, 19720992.
35. Firestein GS. Rheumatoid arthritis in a mouse?. Nat Clin Pract Rheumatol 2009, 5:1. 10.1038/ncprheum0973, 2754140, 19098924.
36. Campbell IK, Rich MJ, Bischof RJ, Hamilton JA. The colony-stimulating factors and collagen-induced arthritis: exacerbation of disease by M-CSF and G-CSF and requirement for endogenous M-CSF. J Leukoc Biol 2000, 68:144-150.
37. Kim KW, Cho ML, Lee SH, Oh HJ, Kang CM, Ju JH, Min SY, Cho YG, Park SH, Kim HY. Human rheumatoid synovial fibroblasts promote osteoclastogenic activity by activating RANKL via TLR-2 and TLR-4 activation. Immunol Lett 2007, 110:54-64. 10.1016/j.imlet.2007.03.004, 17467812.
38. Cohen SB, Dore RK, Lane NE, Ory PA, Peterfy CG, Sharp JT, Heijde D, Zhou L, Tsuji W, Newmark R. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 2008, 58:1299-1309. 10.1002/art.23417, 18438830.
39. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S, Wong T, Campagnuolo G, Moran E, Bogoch ER, Van G, Nguyen LT, Ohashi PS, Lacey DL, Fish E, Boyle WJ, Penninger JM. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999, 402:304-309. 10.1038/46303, 10580503.
40. Ohno H, Uemura Y, Murooka H, Takanashi H, Tokieda T, Ohzeki Y, Kubo K, Serizawa I. The orally-active and selective c-Fms tyrosine kinase inhibitor Ki20227 inhibits disease progression in a collagen-induced arthritis mouse model. Eur J Immunol 2008, 38:283-291. 10.1002/eji.200737199, 18085662.
41. Ohno H, Kubo K, Murooka H, Kobayashi Y, Nishitoba T, Shibuya M, Yoneda T, Isoe T. A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model. Mol Cancer Ther 2006, 5:2634-2643. 10.1158/1535-7163.MCT-05-0313, 17121910.
42. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001, 344:907-916. 10.1056/NEJM200103223441207, 11259725.
43. Lee DM, Friend DS, Gurish MF, Benoist C, Mathis D, Brenner MB. Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science 2002, 297:1689-1692. 10.1126/science.1073176, 12215644.
44. Zhou JS, Xing W, Friend DS, Austen KF, Katz HR. Mast cell deficiency in Kit(W-sh) mice does not impair antibody-mediated arthritis. J Exp Med 2007, 204:2797-2802. 10.1084/jem.20071391, 2118523, 17998392.
45. Tebib J, Mariette X, Bourgeois P, Flipo RM, Gaudin P, Le Loet X, Gineste P, Guy L, Mansfield CD, Moussy A, Dubreuil P, Hermine O, Sibilia J. Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study. Arthritis Res Ther 2009, 11:R95. 10.1186/ar2740, 2714151, 19549290.
46. Watanabe N, Ando K, Yoshida S, Inuzuka S, Kobayashi M, Matsui N, Okamoto T. Gene expression profile analysis of rheumatoid synovial fibroblast cultures revealing the overexpression of genes responsible for tumor-like growth of rheumatoid synovium. Biochem Biophys Res Commun 2002, 294:1121-1129. 10.1016/S0006-291X(02)00608-3, 12074593.
47. Cheon H, Sun YK, Yu SJ, Lee YH, Ji JD, Song GG, Lee JH, Kim MK, Sohn J. Platelet-derived growth factor-AA increases IL-1beta and IL-8 expression and activates NF-kappaB in rheumatoid fibroblast-like synoviocytes. Scand J Immunol 2004, 60:455-462. 10.1111/j.0300-9475.2004.01505.x, 15541037.